Teresa Beninato

Plain English
The APOLLO11 study focused on improving lung cancer research by creating a network that collects and analyzes large amounts of patient data. They built a centralized system to gather real-world information about lung cancer patients, which will help develop better prediction tools for treatment outcomes. This is important because having accurate data can lead to more personalized and effective cancer care. Who this helps: This benefits lung cancer patients and healthcare providers by giving them access to more tailored treatment options.

Plain English
Researchers looked at whether people living in disadvantaged neighborhoods were less likely to have their thyroid surgery performed by experienced surgeons (those doing 50+ surgeries annually). They analyzed nearly 376,000 thyroid surgeries and found that patients from communities with worse education and healthcare resources were significantly less likely to see high-volume surgeons—the ones who typically have better outcomes—while uninsured patients and men were also less likely to get these experienced surgeons. This matters because getting surgery from an experienced surgeon leads to fewer complications, and right now the healthcare system is failing patients from poorer, less-educated communities by funneling them toward less-experienced surgeons.

Plain English
This study looked at how the level of cell division (mitotic activity) in papillary thyroid cancer (PTC) affects the cancer's behavior and the likelihood of it coming back after treatment. Researchers examined data from 640 patients and found that 17.2% had low mitotic activity, which was linked to more aggressive cancer features and a higher chance of recurrence (15.5% for low activity vs. 4.5% for no activity). This is important because understanding these differences can help doctors better predict risks and tailor treatments for patients. Who this helps: This helps patients with papillary thyroid cancer and their doctors.

Plain English
This study looked at how different types of KRAS mutations in patients with advanced non-small cell lung cancer (NSCLC) affect their response to immunotherapy. Among 143 patients, the most common mutation was G12C, and those with bone metastases had a nearly doubled risk of death. Although overall survival rates varied slightly by mutation type, the presence of bone metastases was a significant concern regardless of the specific KRAS mutation, highlighting the need for personalized treatment in these patients. Who this helps: This research benefits lung cancer patients, doctors, and researchers focusing on targeted therapies.

Plain English
This study looked at whether adding radiation therapy (RT) helps patients with adrenocortical carcinoma (ACC) who have had successful tumor removal surgery (called R0 resection). The researchers examined data from 388 patients and found that 51 received adjuvant RT, but there was no difference in survival rates between those who had RT and those who did not. Factors like larger tumor size and higher tumor grade were linked to worse outcomes, but RT did not improve survival for any subgroup of patients. Who this helps: This information benefits doctors and patients deciding on additional treatments after surgery for ACC.

Plain English
This study looked at the difference in payments made by companies to male and female surgeons in the U.S. from 2016 to 2022. It found that male surgeons received, on average, $16,509 more per year than female surgeons, with payments peaking in 2019 at $44,025 for men and $16,677 for women. This matters because it highlights ongoing inequality in financial support for surgeons based on gender, which needs to be addressed to promote fairness in the industry. Who this helps: This helps patients and advocates for gender equity in healthcare.

Plain English
This study looked at the long-term survival of patients with advanced non-small cell lung cancer (NSCLC) who have a high level of a specific protein (PD-L1 ≥50%) and were treated with the drug pembrolizumab. Researchers found that after five years, about 27% of these patients were still alive, with the average length of survival being around 22 months. The findings support the effectiveness of pembrolizumab in real-world settings, highlighting factors like patient age and health status that influence survival outcomes. Who this helps: This helps patients with advanced NSCLC and their doctors in making informed treatment decisions.

Plain English
This study looks at circulating tumor cells (CTCs) in lung cancer, which are tiny cancer cells that escape from tumors into the bloodstream. The researchers found that only certain types of CTCs, especially those with stem-like features, are important for starting new tumors and are more likely to resist treatments. Understanding these specific CTCs could help doctors predict how lung cancer will progress and find better treatment strategies. Who this helps: This benefits doctors and lung cancer patients by providing better insights into their disease and potential treatment options.

Plain English
This study looked at patients with both Graves' disease and papillary thyroid cancer to find out if a specific thyroid antibody called thyroid-stimulating immunoglobulin (TSI) is related to more aggressive cancer characteristics or higher recurrence rates. Out of 96 patients, the majority had low-risk cancer, and the overall recurrence rate was low at 11.5%. The findings showed that TSI levels did not link to aggressive features or cancer recurrence, indicating that TSI may not be a helpful factor in assessing risks in these patients. Who this helps: This helps doctors and patients by clarifying that TSI levels are not a useful indicator of cancer aggression or recurrence in this specific patient group.

Plain English
This study looked at a woman who was first diagnosed with breast cancer at age 34 and then, years later, developed a different type of cancer called large-cell neuroendocrine carcinoma (LCNEC). Genetic testing showed that both cancers had the same mutations, indicating they might be related rather than entirely separate diseases. The patient's treatment included chemotherapy and a drug called pembrolizumab, which led to significant improvement, and as of November 2024, she showed no signs of disease. Who this helps: This information benefits patients with complex cancer cases and their doctors, providing insights for better diagnosis and treatment options.

Plain English
This study focused on patients with advanced non-small cell lung cancer who have a high level of a specific protein (PD-L1 ≥50%) and looked at their long-term outcomes after receiving treatment with pembrolizumab over five years. Researchers found that about one-third of these patients survived beyond five years, and identified key factors that influence survival, such as a patient's overall health, age, and tumor spread. The insights are essential for improving how doctors assess and manage these patients' care over the long term. Who this helps: This research helps doctors and patients by providing better understanding and strategies for long-term cancer care.

Plain English
This study looked at how well a cancer treatment called pembrolizumab works for patients with advanced lung cancer who have low performance status and high PD-L1 expression. Among the 161 patients analyzed, the average survival was 5.4 months, and only 13% survived for five years. The findings show that, while many patients with low performance status don't do well, some can have long-term successes with this treatment, suggesting that doctors shouldn't automatically rule out treatment for these patients based solely on their health status. Who this helps: Patients with advanced lung cancer and low performance status.

Plain English
This study looked at how well small language models can identify cancer-related information in electronic health records (EHRs), specifically focusing on lung cancer data from the APOLLO 11 trial. Researchers tested different ways to design prompts for these models and found that general-purpose models performed better, especially in simpler tasks, while using expert input improved the accuracy of more complex data. This matters because effective extraction of cancer data can help doctors make better decisions and improve patient outcomes by using real-world information securely and accurately. Who this helps: Patients and healthcare providers who rely on accurate cancer data for treatment decisions.

Plain English
This study looked at how well different tyrosine kinase inhibitors (TKIs) work for patients with advanced non-small-cell lung cancer (NSCLC) using real-world health data from electronic records. Researchers found that around 38% of the 190 patients received a newer drug called osimertinib, which resulted in longer treatment duration (15 months) and overall survival (27 months) compared to older TKIs, which had a treatment duration of 10 months and an overall survival of 20.2 months. These findings are important because they provide evidence about the effectiveness of TKIs in everyday practice, helping doctors choose better treatments and informing health policy decisions. Who this helps: This helps patients with advanced lung cancer and their doctors.

Plain English
This research focused on testing an updated tool called ThyraMIRv2, designed to help doctors assess the risk of cancer in uncertain thyroid nodules. The study found that ThyraMIRv2 correctly identified 30.3% of these nodules as needing further examination; however, it did not significantly improve diagnostic accuracy over the previous test version. This matters because it can help doctors make better decisions about surgery for patients with potentially cancerous nodules, despite having a higher chance of false positives. Who this helps: Patients with indeterminate thyroid nodules and their healthcare providers.

Plain English
Researchers examined whether expanding Medicaid (government health insurance for low-income people) helped patients get parathyroid surgery at the best hospitals. They analyzed data from nearly 32,000 patients and found that Medicaid expansion significantly improved access—Medicaid patients in expansion states were 12-21 times more likely to receive surgery at high-quality, high-volume centers compared to those in non-expansion states. However, the study revealed a troubling gap: uninsured and Medicaid patients overall were still much more likely to have surgery at lower-quality, low-volume hospitals compared to privately insured patients, even after expansion. Medicare patients fared reasonably well at high-volume centers. The bottom line is that while Medicaid expansion helped, insurance status remains a major barrier to accessing the best surgical care—and patients without insurance or with Medicaid still face significant disadvantages compared to the privately

Plain English
This study looked at how to improve treatment options for patients with advanced lung cancer by combining various types of medical data from multiple clinics in Italy. Researchers gathered information from blood and tissue samples, as well as clinical and imaging data, to create a comprehensive tool that helps doctors choose the best therapies based on individual patient conditions. This matters because it aims to refine treatment decisions, potentially improving outcomes for these patients; the study involves a large dataset that can better predict how different therapies will work for different people. Who this helps: Patients with advanced lung cancer.

Plain English
This study looked at whether giving radioactive iodine improves survival in patients with a specific type of thyroid cancer, known as classic papillary thyroid carcinoma, that is larger than 4 centimeters and still located in the thyroid. Researchers found that after ten years, the chance of surviving this cancer was very similar for those who received radioactive iodine (97.2%) and those who did not (95.6%). This means that radioactive iodine does not significantly improve survival for these patients, suggesting that this treatment might not be necessary for them. Who this helps: This research benefits thyroid cancer patients and doctors by providing clearer treatment guidelines.

Plain English
This study looks at a patient with advanced lung cancer that has a specific genetic change called ALK rearrangement, who was treated with multiple ALK-targeting drugs over time. The patient had experienced resistance to earlier treatments but responded well to a drug called lorlatinib after their cancer progressed, showing that the treatment can still be effective even after previous failures. Specifically, the patient gained a long-term reduction in disease after the drug was reintroduced, demonstrating that understanding the specific mutations in cancer can help tailor treatments for better results. Who this helps: This benefits patients with ALK-rearranged lung cancer by offering hope for effective treatment options after standard therapies fail.

Plain English
The G-DEFINER study focused on understanding how immune-related side effects from cancer treatments differ between male and female patients. The study aimed to gather data from 250 patients, down from the original goal of 400 due to delays caused by the COVID pandemic. By identifying differences in side effects based on gender and other factors, the research hopes to lead to better, more personalized treatment strategies for cancer patients. Who this helps: This helps cancer patients and their doctors.

Plain English
This study looked at how often the aggressive types of papillary thyroid cancer (PTC) are reported at different medical facilities across the U.S. It was found that 67% of these aggressive cases were reported by academic hospitals, while other facilities were 1.4 to 2.0 times less likely to report them. Additionally, the patients with these aggressive types had a slightly lower chance of surviving for five years compared to those with the classic type of PTC (90.5% versus 94.5%). Who this helps: This research helps doctors by highlighting the importance of accurate reporting and diagnosis of aggressive thyroid cancer types.

Plain English
This study looked at the effects of adding a drug called ramucirumab to standard chemotherapy drugs, carboplatin and paclitaxel, for treating a rare and aggressive cancer called thymic carcinoma. In a group of 35 patients, 80% showed a positive response to the treatment, with a median survival rate of about 44 months. These results are significant because they indicate that this combination therapy could be an effective first-line treatment option for patients with advanced thymic carcinoma. Who this helps: This helps patients with advanced thymic carcinoma and their doctors in making treatment decisions.

Plain English
Researchers studied how proton pump inhibitors (PPIs), which are used to treat stomach issues, affect cancer treatments in patients with metastatic renal cancer. They found that for patients taking pazopanib and cabozantinib, those using PPIs had shorter progression-free survival (PFS)—24.7 months compared to 38 months for those not using PPIs. There wasn’t a significant impact for those on sunitinib. This matters because it highlights the need for careful consideration when prescribing PPIs alongside specific cancer medications. Who this helps: This helps patients with metastatic renal cancer and their doctors.

Plain English
This study reviews the latest treatments for pleural mesothelioma, a rare cancer, highlighting the effectiveness of immune therapies alongside traditional chemotherapy. It found that certain genetic changes in patients could be targeted with specific drugs, which may improve outcomes; for example, patients with a loss of the CDKN2A gene might benefit from CDK4/6 inhibitors. The research is important because it points to a future where treatments can be tailored to individual patients, potentially leading to better survival rates. Who this helps: This helps patients with pleural mesothelioma and their doctors.

Plain English
This study looked at how immunotherapy affects the survival of patients with gastrointestinal cancers that have spread to the liver. Researchers found that patients receiving immunotherapy combined with chemotherapy lived longer, with a survival improvement of about 23% compared to those who only received chemotherapy. Using other treatments like radiation alongside immunotherapy also showed better survival rates, highlighting the potential benefits of combining these therapies. Who this helps: This research benefits cancer patients with liver metastases and their doctors by providing insights into more effective treatment options.

Plain English
This study looked at how race and ethnicity affect the likelihood of finding invasive tumors in patients undergoing surgery for a precancerous condition of the pancreas called intraductal papillary mucinous neoplasms. Out of 4,505 cases examined, 20.5% had invasive cancer, with Black patients at 24.2%, Asian patients at 23.7%, and Hispanic patients at 22.6%, compared to 19.9% for non-Hispanic White patients. This difference in invasive cases can't be explained by overall health or age factors, which means that non-White patients face higher risks, and recognizing this can help doctors improve early interventions and treatment strategies. Who this helps: This helps patients from diverse racial and ethnic backgrounds facing pancreatic cancer risks.

Plain English
This study looked at two types of appendiceal cancer—mucinous and non-mucinous—and how much of the tumor needs to be surgically removed to improve survival. Out of nearly 4,700 patients, 68% had their entire colon removed, and while this helped patients with non-mucinous cancer (especially those with medium to high tumor grades), it didn't improve survival for those with mucinous cancer at all. This finding suggests that patients with mucinous appendiceal adenocarcinoma might not need such extensive surgery, which could reduce unnecessary procedures and their associated risks. Who this helps: This helps patients with mucinous appendiceal cancer by potentially sparing them from more invasive surgery.

Plain English
Researchers studied how a specific testing method for thyroid nodules with RAS mutations can guide treatment decisions. They found that 32.3% of the tested nodules were classified as positive, meaning there was a 10% or greater risk of cancer, leading to much higher rates of surgery and confirmed cancer (74.4% of positive nodules were surgically removed, and 46.4% of those had cancer). However, the test did not effectively distinguish between benign and malignant nodules, meaning doctors should consider surgery for all RAS-mutated nodules regardless of test results. Who this helps: This helps patients with thyroid nodules and their doctors in making informed treatment decisions.

Plain English
This study looked at how to find the best method for locating problem areas in patients with recurring primary hyperparathyroidism who need another surgery. It found that using ultrasound followed by a fine-needle aspiration and a PTH test is the most cost-effective approach. When ultrasound does not identify the issue, four-dimensional computed tomography (4D-CT) is the next best option. These findings matter because they help healthcare providers choose tests that save money while still effectively identifying the problem. Who this helps: This helps patients needing repeat surgery for hyperparathyroidism and their doctors.

Plain English
Researchers examined surgery records from 515 U.S. hospitals between 2019 and 2022 to see how COVID-19 affected surgeries on the thyroid, parathyroid, and adrenal glands. When the pandemic started in early 2020, most of these surgeries dropped sharply, but patients needing emergency adrenal cancer surgery still got treated; outpatient procedures bounced back to normal levels within a couple of years, while hospital-based thyroid and parathyroid surgeries remained below pre-pandemic numbers through 2022. This matters because patients waiting for these surgeries faced delays and complications, and the data shows that the healthcare system's recovery was uneven—some patients got faster access to care than others depending on the type of surgery and whether it required overnight hospitalization.

Plain English
Researchers looked at whether hospitals that perform more of a specific cancer surgery (called CRS/HIPEC, which involves removing tumors and bathing the abdomen with heated chemotherapy) get better results than hospitals that do fewer of these operations. They examined over 5,000 procedures across 149 hospitals between 2020 and 2022. They found no meaningful difference in patient outcomes—including complications, deaths, hospital stays, or readmissions—regardless of whether a hospital performed 4 cases a year or 47 cases a year. The only minor difference was that low-volume hospitals sent more patients to the ICU after surgery, but this didn't translate to worse overall results. This matters because it shows that for this particular procedure, hospitals don't need to do hundreds of these surgeries to get good results—experience at a basic level is apparently enough, at least in well-equipped academic medical centers.

Plain English
Researchers analyzed 68 lawsuits filed against surgeons for malpractice after thyroid surgery between 1949 and 2022, looking at what factors determined whether surgeons won or lost. Surgeons won about 78% of cases overall, and won even more often (92%) when cases were tried at academic hospitals or handled by surgeons with specialized endocrine training—they also won more frequently in states with legal protections for doctors. The most common problem leading to lawsuits was nerve damage during surgery, and when patients did win, they received damage awards averaging around $570,000.

Plain English
Researchers tracked cancer surgeries for the pancreas and liver during COVID-19 to see if the pandemic disrupted treatment. They found that pancreatic cancer surgeries continued at normal rates throughout the pandemic, while liver cancer surgeries dropped briefly at the start but quickly returned to normal levels—and more pancreatic cancer patients received chemotherapy before surgery during the pandemic. This matters because it shows hospitals prioritized cancer operations during COVID-19, meaning patients with these deadly cancers didn't face major treatment delays, though the increased use of pre-surgery chemotherapy suggests doctors may have changed their approach to managing these patients.

Plain English
Researchers studied whether expanding Medicaid (health insurance for low-income people) helped patients get thyroid surgery at the best hospitals—ones that perform many surgeries and have better outcomes. They found that while Medicaid expansion did get more low-income people insured, those patients still ended up having surgery at smaller, lower-volume hospitals instead of the best ones, whereas privately insured patients went to high-volume centers. This matters because patients who have surgery at experienced, high-volume hospitals recover better and have fewer complications, so Medicaid patients are being disadvantaged even with expanded insurance coverage.

Plain English
Researchers studied ultrasound images of 119 lymph nodes in patients with thyroid cancer to figure out which visual signs best indicate the cancer has spread to those nodes. They found that four specific signs together—enlarged size, lost fatty tissue in the center, disrupted internal structure, and tiny calcium deposits—are the most reliable combination for identifying cancerous nodes, correctly identifying cancer 88% of the time when all four signs are present. This matters because doctors currently use these ultrasound signs to decide whether to biopsy suspicious lymph nodes, but there's been no clear consensus on which signs matter most; this research provides a concrete answer that could help doctors make faster, more accurate decisions about which patients actually need biopsies.

Plain English
Researchers compared how often patients needed a second surgery after having either half their thyroid removed (lobectomy) or their entire thyroid removed for cancer, before and after 2015 guidelines made the less-invasive half-removal option more acceptable. They found that while doctors increasingly chose the half-removal option after 2015, patients who had it needed fewer immediate second surgeries (likely because doctors got better at doing the procedure right the first time), and they weren't any more likely to need surgery later for cancer recurrence compared to patients who had their whole thyroid removed. The finding matters because it shows that the less-invasive surgery can be a safe and effective option for patients with low-risk thyroid cancer, potentially allowing them to avoid the side effects of removing their entire thyroid while not compromising their long-term outcomes.

Plain English
This study looked at the effects of a drug called sunitinib on patients with two rare types of tumors: type B3 thymoma and thymic carcinoma. Among 32 patients with thymic carcinoma, about 21.7% saw a positive response to the treatment, while type B3 thymoma did not show any response. The results also indicated that patients with thymic carcinoma had a disease control rate of 89.3%, with a median overall survival of 27.8 months. This research is important because it highlights sunitinib as a possible second-line treatment option for patients with thymic carcinoma, though it may cause significant side effects. Who this helps: This helps patients with thymic carcinoma and their doctors.

Plain English
In this study, researchers looked at patients with advanced non-small cell lung cancer (NSCLC) who have a specific marker called PD-L1 below 50%. They found that the presence of certain immune cells in the blood, like specific natural killer cells and lymphocytes, as well as high levels of certain proteins, were linked to longer periods without cancer progression. For instance, higher natural killer cell counts correlated with about 44% lower risk of cancer worsening. Who this helps: This research benefits patients with advanced NSCLC by improving the way doctors can predict which patients might respond better to treatment.

Plain English
This study looked at how treating secondary hyperparathyroidism (sHPT) in kidney transplant patients affects their health after the transplant. Researchers found that patients who had surgery to remove the parathyroid glands (parathyroidectomy) before their transplant had better control of their hormone levels and lower rates of developing a more severe condition (tertiary hyperparathyroidism, tHPT) afterwards, with only 5.9% of those treated surgically developing tHPT compared to 42.1% of those treated with medication (cinacalcet). This matters because it shows that surgical treatment can lead to better long-term health outcomes for kidney transplant patients. Who this helps: Patients undergoing kidney transplants with a history of secondary hyperparathyroidism.

Plain English
This study looked at how well immunotherapy treatments work for patients with advanced non-small-cell lung cancer, especially those with new types of genetic mutations called driver alterations. They found that patients with these novel alterations lived longer (25.1 months) than those without them (9.37 months), although the improvement in other measures of treatment success was less clear. Combining immunotherapy with chemotherapy led to better outcomes than using immunotherapy alone, showing that these treatments can be beneficial even for patients with these specific mutations. Who this helps: This helps patients with advanced non-small-cell lung cancer and their doctors by providing insights into effective treatment options.

Plain English
This study looked at how treating advanced non-small cell lung cancer (NSCLC) patients with both bone-targeted agents (BTAs), like denosumab, and immune treatments affects their survival, especially those with a high number of bone tumors. They found that patients with high bone tumor burden (three or more bone metastases) who received these combined treatments lived longer—an average of 8.3 months compared to 3.5 months for those without high tumor burden. This is significant because it highlights that identifying patients with high bone tumor burden can guide better treatment strategies and improve survival outcomes for them. Who this helps: This research benefits patients with advanced lung cancer and their doctors by providing insights on effective treatment options.

Plain English
This study looked at the number and characteristics of subspecialist doctors who teach Obstetrics and Gynecology (OBGYN) residents across the United States. Researchers found that there are 4,659 subspecialist faculty members at 278 residency programs, making up 81.5% of the subspecialist workforce in OBGYN. Notably, 59.9% of these subspecialists are women, and they are mainly located in 45 states, with a significant portion (49.7%) teaching at the main residency program sites; this matters because a strong faculty helps train the next generation of doctors in key women's health areas. Who this helps: This helps OBGYN residents and ultimately benefits patients seeking specialized care.

Plain English
This study looked at whether surgical residents should do their dedicated research after their second or third year of training. Researchers found that 73% of residents completed dedicated research, and those who did it after their second year published more basic science papers (an average of 1 compared to none for those who researched after the third year). This finding matters because residents aiming for fellowships that emphasize basic science research might improve their chances of standing out if they conduct research earlier in their residency. Who this helps: This helps surgical residents looking to enhance their academic profiles and improve their fellowship applications.

Plain English
This research looked at the link between specific genetic changes (mutations) and how they affect the behavior of pancreatic cancer cells in tumors from 321 patients. The study found that 26.8% of the patients had these mutations, and while some were linked to poorer survival rates, especially in specific conditions, the mutations themselves did not affect the cancer's characteristics or patient outcomes. This means more targeted clinical trials are needed to improve treatment for pancreatic cancer. Who this helps: This helps patients with pancreatic cancer and their doctors by identifying the need for better treatment options.

Plain English
Researchers examined how COVID-19 affected surgery rates for gut cancers across the United States from 2019 to 2022, analyzing nearly 96,000 operations on the esophagus, stomach, colon, and rectum. They found that surgery for esophageal and rectal cancers dropped significantly and stayed low throughout the pandemic, while stomach and colon cancer surgeries initially fell but bounced back to normal levels within a few months. This matters because delays in cancer surgery can allow tumors to grow and spread, potentially worsening patient outcomes and survival rates.